LATEST NEWS
Could more complex molecular analysis aid biomarker-driven clinical management of poor-prognosis colorectal cancer?
New study findings provide support for the use of ctDNA to predict survival benefits and personalise treatments
Treatment duration of immunotherapy combination does not impact on disease-free survival in dMMR colon cancer
An ATOMIC study pre-planned exploratory analysis reports no DFS benefit with the addition of immunotherapy in patients receiving fewer than six cycles of chemotherapy
Adagrasib plus cetuximab fails to outperform chemotherapy in KRAS G12C-mutated metastatic colorectal cancer
The phase III KRYSTAL-10 trial did not meet its co-primary survival endpoints
AI & DIGITAL ONCOLOGY
Multimodal AI biomarkers: from biology to patient stratification
Artificial intelligence is enabling a new class of biomarkers by integrating histology, molecular data, imaging, and clinical records to generate scalable, biologically grounded insights for precision oncology.
AI-driven multimodal strategy improves risk stratification in early breast cancer
Integrating digital pathology with genomic and clinical data may enhance prediction of late recurrence and refine selection for adjuvant treatment intensification in HR-positive, HER2-negative disease
Customised app shows promise for monitoring prostate cancer patients in real-time
A pilot study reports high levels of acceptance and compliance despite an older patient population
TREATMENT OPTIMISATION
Immunotherapy in dMMR/MSI-H endometrial cancer – a true game-changer?
Long-term dostarlimab data suggest that immunotherapy may be used with curative intent in this difficult-to-treat population
Is there a role for intensification immunotherapy in patients with locally advanced cervical cancer?
Immunotherapy is optimising outcomes in LACC, with durable responses and long-term survival, especially in those with immune activated or ‘hot’ tumours
Targeting the CD47-SIRPα axis continues to show promise in solid tumours
In early-phase studies, two novel agents showed low propensity to induce heamatological toxicities in heavily pre-treated solid tumours
OPINIONS
Rethinking cancer vaccines through the tumour immunopeptidome
Juliane Walz
Reshaping the treatment landscape for GI cancers
Elizabeth Smyth
ctDNA is unlocking new clinical opportunities for liquid biopsy
Kosei Hasegawa
Annual PSA screening in men with BRCA2 mutations at high genetic risk of prostate cancer
Heather H. Cheng
Optimal sequencing of immunotherapy in MSI-H/dMMR colon cancer remains uncertain
Dominik Modest
OPINIONS
Rethinking cancer vaccines through the tumour immunopeptidome
Juliane Walz
Reshaping the treatment landscape for GI cancers
Elizabeth Smyth
ctDNA is unlocking new clinical opportunities for liquid biopsy
Kosei Hasegawa
Annual PSA screening in men with BRCA2 mutations at high genetic risk of prostate cancer
Heather H. Cheng
Optimal sequencing of immunotherapy in MSI-H/dMMR colon cancer remains uncertain
Dominik Modest